BEDMINSTER, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused...
EDEN PRAIRIE, Minn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a...
BOSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering...
CHATHAM, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today...
Awarded Extension to Existing Supply Tender which relates to Portfolio of Four Specialty IgG Products Acquired in 2021Supply Extension Secures...
– Study reveals the structural basis of receptor activation and signaling by IL-27 cytokine –– Study elucidates how SRF388 binds to...
Amryt to Report Q3 2022 Results on November 3, 2022 DUBLIN, Ireland, and Boston MA, October 19, 2022, Amryt (Nasdaq:...
BRANFORD, Conn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells...
Two Breckenridge Staples Launch Second Annual Buddy Pass, Limited-Edition Whiskey and Beer Across the U.S. The Second Annual Buddy Pass,...
Proceeds will support nursing scholarships across Canada with a focus on inclusion, diversity, equity and accessibility to help address critical...
ReSPECT-LM Phase 1 clinical trial selected as TOP Trials Oral Presentation Treatment was well tolerated without dose limiting toxicities and...
-- Data to be presented from CORAL-BOOST and CORAL-CEPI trials evaluating Gritstone’s samRNA vaccine candidates against SARS-CoV-2 -- EMERYVILLE, Calif.,...
NEW YORK, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA), a biotechnology company developing breakthrough immunomodulation therapies...
CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of...
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase...
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase...
Topline Data Expected December 2022CARSON CITY, Nev., Oct. 19, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the...
Expanded partnership covers biosimilar candidates in immunology and oncologyREYKJAVIK, Iceland and BOUCHERVILLE, Quebec, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Alvotech...
Expanded partnership covers biosimilar candidates in immunology and oncologyAlvotech (NASDAQ: ALVO), a global biotech company specializing in the development and...
Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver...